Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
USFDA’s list of drugs that need generic alternatives
In
its continuous endeavor to bolster the competitiveness of the generics
market, the US Food
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
PharmaFlow in October: Deal making picks up; Pharma companies invest in capacity building
The year
2018 has witnessed a record-setting pace in approvals of new drugs. By early
November, th
FDA to strengthen drug manufacturing inspections; A person of Indian origin to head Novartis
This week in Phispers, we introduce you to Vas Narasimhan, the new CEO set to head Novartis in Febru
Drug costs and prescription trends in the United States: Analyzing Medicare’s $121 billion spend
In less than three weeks, Donald Trump will assume office as the
President of the United States. He
Sandoz, Mylan, Hetero, Lupin face the heat due to data manipulation at Semler
In April 2016, the US Food and Drug Administration (FDA) came
down heavily on Semler Research Center
Phispers: India may ban animal-derived gelatin capsules; FDA Warning Letter trends, next-gen Nexium & more
Here’s this week’s pharma news capsule – Phispers (Pharmaceutical Whispers) &ndas
FDA’s Drug Approvals in 2015: Novel Drugs & New Versions of Existing Drugs
Each year,
the US Food and Drug Administration (FDA) approve hundreds
of new medications. A small su
Haunted: Teva’s $1.2 billion ‘pay-for-delay’ penalty; which companies will get hit next?
Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total payment of
